Related Experiment Videos
[Thrombocytopenia due to glibenclamide]
Harefuah
|April 1, 1992
Summary
Glibenclamide, a sulfonylurea medication, can rarely cause severe thrombocytopenia (low platelet count) and bleeding. Regular platelet monitoring is recommended after starting glibenclamide to detect this rare side effect early.
Area of Science:
- Internal Medicine
- Pharmacology
- Hematology
Background:
- Glibenclamide is a short-acting sulfonylurea commonly used for type 2 diabetes management.
- Drug-induced thrombocytopenia is a known but infrequent adverse effect of various medications.
- Sulfonylureas, as a class, have been associated with hematological side effects.
Observation:
- A 45-year-old male patient presented with severe thrombocytopenia and a bleeding tendency.
- The patient's symptoms were temporally related to the initiation of glibenclamide treatment.
- This case highlights a rare adverse reaction to glibenclamide.
Findings:
- The patient developed thrombocytopenic purpura, a serious condition characterized by low platelet counts and purpura.
- The thrombocytopenia was directly attributed to glibenclamide administration.
- This finding underscores the potential for glibenclamide to induce immune-mediated platelet destruction.
Implications:
- Healthcare providers should be vigilant for thrombocytopenia in patients treated with glibenclamide.
- Routine platelet count monitoring is advised shortly after initiating glibenclamide therapy.
- Consideration should be given to periodic platelet count checks (e.g., every 3 months) during long-term glibenclamide use.